LX9851 Phase 1 Milestone Masks Unvalidated ACSL5 Mechanism Against Entrenched GLP-1 Incumbents

Lexicon Earns $10M Milestone for LX9851 Phase 1 Progress

Lexicon Pharmaceuticals, Inc. announced it has earned a third $10 million milestone payment from Novo Nordisk A/S in 2026. This payment was triggered by the achievement of a key patient dosing milestone in the ongoing Phase 1 clinical development program for LX9851. LX9851 is a first-in-class oral small molecule inhibitor of ACSL5, being developed by Novo Nordisk for obesity and associated metabolic disorders under an exclusive worldwide license agreement signed in 2025. With this, Lexicon has now accumulated $75 million out of a potential $1 billion in total upfront and milestone payments from the collaboration, in addition to future tiered royalties on net sales. The Phase 1 program, initiated in March 2026, is investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of LX9851 in overweight or obese adults and is expected to conclude in the first quarter of 2027.

• Lexicon Pharmaceuticals has received its third $10 million milestone payment from Novo Nordisk in 2026, bringing the total earned from the collaboration to $75 million. This financial achievement is part of a broader agreement that could see Lexicon receive up to $1 billion in upfront, development, regulatory, and commercial milestone payments, alongside tiered royalties on future net sales of LX9851, highlighting the significant financial potential of the partnership.
• The milestone payment signifies a crucial advancement in the clinical development of LX9851, specifically a key patient dosing achievement in its ongoing Phase 1 program. The rapid progression of LX9851 from a licensing agreement in 2025 to the successful completion of multiple clinical development milestones in just over a year demonstrates the strong execution and momentum of the collaboration between Lexicon and Novo Nordisk.
• LX9851 is a novel, first-in-class oral small molecule that acts as a potent and selective inhibitor of Acyl CoA Synthetase 5 (ACSL5), a key enzyme in metabolic pathways regulating fat accumulation and energy balance. Preclinical data presented at Obesity Week 2024 showed that LX9851, both alone and in combination with semaglutide, significantly reduced weight, food intake, and fat mass, and also mitigated weight regain, suggesting its potential as an important new therapeutic approach for obesity and metabolic disorders.

Designing the Phase 1 Trial for LX9851 in Obesity

Phase 1 trial design for a novel asset like LX9851 benefits from benchmarking against the methodological frameworks established in pivotal obesity and metabolic disorder trials. The studies summarized below span a range of interventional approaches — from GLP-1-based therapies to dietary and combinatorial regimens — and collectively illustrate the endpoint constructs, population criteria, and trial durations that define the current evidence landscape. These parameters offer a useful reference for informing first-in-human study architecture.

Overcoming Current Limitations in Obesity Treatment

Current obesity management is constrained by a complex interplay of biological, pharmacological, surgical, and behavioral factors that collectively limit the durability and tolerability of available interventions. Addressing these challenges is critical for developing more effective, long-term therapeutic strategies for obesity and its associated metabolic disorders.

• Hormonal and metabolic resistance to weight loss maintenance: Following diet-induced weight loss, the body enacts sustained hormonal counter-regulatory responses — including decreases in leptin, peptide YY, cholecystokinin, and insulin, alongside increases in ghrelin, GLP-1, GIP, and pancreatic polypeptide — that actively promote weight regain for at least one year post-reduction. Compounding this, adaptive thermogenesis results in a meaningful reduction in resting metabolic rate (−291 ± 226 kcal/day), with an adaptive thermogenesis component of −150 ± 162 kcal/day maintained long-term. Dopaminergic signaling further amplifies cravings for energy-dense foods following weight loss.

• Limited durability of non-surgical interventions: Conventional approaches — dietary modification, increased physical activity, and pharmacotherapy — yield predominantly transient weight reduction. Given that approximately 50% of weight variance is genetically determined and the remaining 50% driven by obesogenic environmental factors, sustained weight control through lifestyle and medical management alone remains exceptionally difficult.

• Gastrointestinal tolerability burden with GLP-1-based therapies: GLP-1 receptor agonists and co-agonists, including semaglutide and tirzepatide, are associated with high rates of gastrointestinal adverse events — nausea, vomiting, diarrhea, and constipation — particularly during dose escalation. Adverse event incidence ranges from 80%–97% in treated patients versus 63%–100% in placebo groups, with GI-specific events occurring in 47%–84% versus 13%–63%, respectively. Treatment discontinuation due to adverse events is reported in up to 26% of treated patients compared to 9% with placebo.

• Loss of lean body mass with GLP-1 receptor agonist therapy: Weight reduction achieved with GLP-1RAs is consistently accompanied by decreases in lean body mass, posing particular concern in populations already predisposed to sarcopenia. Loss of muscle mass and strength impairs mobility, worsens insulin resistance, accelerates cardiometabolic decline, and increases mortality risk — outcomes exacerbated by the chronic inflammation, mitochondrial dysfunction, and altered protein metabolism characteristic of metabolic disease.

• Surgical risks and long-term complications of bariatric procedures: While bariatric surgery offers durable weight loss, it carries a clinically significant complication profile. Early postoperative risks include anastomotic leakage, venous thromboembolism, bleeding, and rhabdomyolysis. Late complications encompass dumping syndrome, marginal ulcers, nephrolithiasis, osteoporosis, nutritional and vitamin deficiencies (some precipitating neurologic disorders), elevated rates of substance abuse, and increased suicide risk. Roux-en-Y gastric bypass is further associated with weight regain over time and potential need for reoperation due to small bowel obstruction, internal hernia, intussusception, or anastomotic complications.

• Requirement for indefinite pharmacological treatment: Evidence indicates that GLP-1-based pharmacotherapy must be maintained long-term to preserve weight loss outcomes. Discontinuation predictably results in weight regain — predominantly as fat mass — underscoring the absence of a finite treatment course and raising questions around patient adherence, access, and healthcare system sustainability.

• Psychological and behavioral contributors to weight regain: Stress-related and emotional eating are identified as primary drivers of weight regain following weight loss interventions, highlighting the insufficiency of pharmacological and surgical approaches alone. The psychological dimensions of eating behavior represent a critical, often undertreated, factor that attenuates long-term weight loss maintenance.

LX9851: Charting a Novel Oral Path in Obesity

The recent $10 million milestone payment to Lexicon Pharmaceuticals from Novo Nordisk for LX9851 marks a significant moment in the ongoing quest for effective obesity treatments. This payment, triggered by a key patient dosing milestone in the Phase 1 program, underscores the industry's keen interest in novel mechanisms, particularly oral therapies, to address the global obesity epidemic.

LX9851 is a first-in-class oral inhibitor of acyl-CoA synthetase 5 (ACSL5), an enzyme with a critical role in fatty acid metabolism. Research indicates that inhibiting intestinal ACSL5 can protect against diet-induced obesity by enhancing satiety and reducing food intake. This occurs through an intriguing mechanism: increased postprandial secretion of gut hormones like GLP-1 and PYY, which are known to regulate appetite. This indirect modulation of satiety pathways offers a distinct approach compared to the direct agonism of GLP-1 receptors seen with many leading injectable therapies.

For Novo Nordisk, a dominant force in the obesity market with agents like Amycretin showing impressive weight loss in early trials, investing in LX9851 represents a strategic move to diversify its pipeline. An oral, differentiated mechanism could broaden its market reach, potentially appealing to patients seeking alternatives to injectables or those who may not respond optimally to existing therapies. For Lexicon, this collaboration provides substantial validation of its drug discovery platform and a significant financial runway, with potential milestones reaching $1 billion.

However, the path forward is not without its challenges. ACSL5 is known to play pleiotropic roles in various tissues, including promoting glioma cell survival and influencing hepatocyte apoptosis. This raises considerations regarding potential off-target effects or systemic impacts that will need careful monitoring in clinical development. Furthermore, preclinical data suggest that the protective effects of ACSL5 deficiency against obesity are primarily observed in the context of high-fat diets, which might imply a more specific patient population or dietary context for optimal efficacy. The competitive landscape, characterized by highly effective GLP-1 agonists, sets a demanding benchmark for any new obesity treatment. LX9851 will need to demonstrate compelling efficacy, a favorable safety profile, and clear differentiation to carve out a meaningful position in this rapidly evolving market. The upcoming Phase 1 results in early 2027 will be crucial in shedding more light on its potential.